Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux

ROCHESTER, N.Y. -- Bausch & Lomb, the global eye health company, today announced it has acquired the commercial assets of Tubilux Pharma S.p.A.

Tubilux is a privately held ophthalmic pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products primarily in Italy, and with distribution in approximately 30 other countries.

Under the terms of the agreement, Bausch & Lomb has acquired the company’s ophthalmic pharmaceuticals portfolio, as well as its commercial and sales operations. Group Tubilux will retain its manufacturing operation, producing existing products for Bausch & Lomb under a multi-year contract.

“This agreement more than doubles our presence in the Italian ophthalmic pharmaceuticals market,” said Charl van Zyl, head of Bausch & Lomb’s Pharmaceuticals business for Europe, Middle East and Africa. “Bausch & Lomb is committed to expanding our portfolio offerings, and we believe that this investment will prove successful for the company, doctors and patients alike.”

The acquired Tubilux portfolio includes products for dry eye relief (Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).

“As a result of this transaction, Tubilux will strengthen its focus and presence in the ophthalmic pharmaceutical contract manufacturing sector, including ointments, gels and eye drop formats,” said Emidio Fedeli, chief executive officer of Group Tubilux.

Sal Oppenheim Jr. & Cie. KGaA Milan Branch acted as the sole financial advisor of Group Tubilux in this transaction.

Financial terms of the agreement will not be made public.